← Database
M&A

COOPER-VEMEDIA

Acquired by

CVC

FRANCE Life Sciences EV [1b EUR - 100b EUR] 03/2021

Target

COOPER-VEMEDIA

Acquirer

CVC

Context

CVC acquired a majority stake in Cooper-Vemedia from Charterhouse. The transaction, valued at EUR2.2 billion, was won in a competitive process against a PAI/Ontario Teachers' consortium. The acquisition reflects CVC's appetite for high-cash-flow businesses with low capital intensity (Capex ~EUR10M). The goal is to pursue a buy-and-build strategy across Europe.

COOPER-VEMEDIA, which reported an EBITDA margin of LOGIN in 2020, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN premium to the 12.8x average currently observed in the Healthcare & Pharma sector.

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

A leading European consumer healthcare platform specialized in over-the-counter (OTC) treatments. Its portfolio includes iconic brands such as Oenobiol, Audispray, Mercurochrome, and Dakin. The group operates as both a manufacturer and a powerful distributor with a massive pharmacy network.

Ent. Value

LOGIN

Equity Value

LOGIN

Multiples Analysis

EV / Revenue

LOGIN

EV / EBITDA

LOGIN

EV / EBIT

LOGIN

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2020
LOGIN
LOGIN
LOGIN
2019
LOGIN
LOGIN
LOGIN

Other operations with COOPER-VEMEDIA

mynth data is contributed by M&A / PE professionals and systematically cross-verified against private deal documents and official releases. All source materials are destroyed post-validation to guarantee data anonymity and compliance.